{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:05:11Z","timestamp":1793034311696,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"crossref","award":["1718-HQ-000027"],"award-info":[{"award-number":["1718-HQ-000027"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003400","name":"Ontario Ministry of Research, Innovation and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NIDA DP2-DA040256"],"award-info":[{"award-number":["NIDA DP2-DA040256"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The increasing incidence of fatal opioid overdose is a public health crisis in Canada. Given growing consensus that this crisis is related to the presence of highly potent opioid adulterants (e.g., fentanyl) in the unregulated drug supply, drug checking services (DCS) have emerged as part of a comprehensive approach to overdose prevention. In Canada\u2019s largest city, Toronto, a network of DCS launched in 2019 to prevent overdose and overdose-related risk behaviors. This network employs mass spectrometry technologies, with intake sites co-located with supervised consumption services (SCS) at three frontline harm reduction agencies. The protocol and rationale for assessing the impact of this multi-site DCS network in Toronto is described herein. The aims of this study are to (1) evaluate the impact of DCS access on changes in and factors influencing overdose and related risk behaviors, (2) investigate the perceived capacity of DCS to prevent overdose, and (3) identify composition (qualitative and quantitative) trends in Toronto\u2019s unregulated drug supply.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will use a parallel-mixed-methods design with complementary data sources (including data from chemical analysis of drug samples, quantitative intake and post-test surveys, SCS, coroners, paramedic services, and qualitative interviews), followed by a meta-inference process wherein results from analyses are synthesized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Whereas most DCS globally target \u201crecreational drug users,\u201d in Toronto, this networked DCS will primarily target marginalized people who use drugs accessing frontline services, many of whom use drugs regularly and by injection. This evolution in the application of DCS poses important questions that have not yet been explored, including optimal service delivery models and technologies, as well as unique barriers for this population. Increasing information on the unregulated drug supply may modify the risk environment for this population of people who use drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study addresses evidence gaps on the emerging continuum of overdose prevention responses and will generate critical evidence on a novel approach to reducing the ongoing high incidence of drug-related morbidity and mortality in Canada and elsewhere.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-019-0336-0","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T17:03:52Z","timestamp":1584983032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale"],"prefix":"10.1186","volume":"17","author":[{"name":"Drug Checking Services in Toronto Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maghsoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Beriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Barnaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Altenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nisenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Leece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Tupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kufner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Scheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-9386","authenticated-orcid":false,"given":"D.","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"336_CR1","unstructured":"National Report: Apparent opioid-related deaths in Canada. Government of Canada; 2019."},{"key":"336_CR2","doi-asserted-by":"crossref","unstructured":"Ye X, Sutherland J, Henry B, Tyndall M, Kendall PRW. Impact of drug overdose-related deaths on life expectancy at birth in British Columbia. Health Promot Chronic Dis Prev Can. Research, Policy & Practice. 2018;38(6).","DOI":"10.24095\/hpcdp.38.6.05"},{"issue":"9","key":"336_CR3","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.12598","volume":"109","author":"T Gomes","year":"2014","unstructured":"Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction. 2014;109(9):1482\u20138.","journal-title":"Addiction"},{"key":"336_CR4","unstructured":"Toronto Overdose Information System Toronto. Toronto Public Health; 2018. Available from: https:\/\/www.toronto.ca\/community-people\/health-wellness-care\/health-inspections-monitoring\/toronto-overdose-information-system\/. Accessed 29 Apr 2019."},{"key":"336_CR5","unstructured":"Illicit drug overdose deaths in BC: January 1, 2007 \u2013 June 30, 2017. B.C. Coroners Service; 2017. Retrieved from http:\/\/www2.gov.bc.ca\/assets\/gov\/public-safety-and-emergency-services\/death-investigation\/statistical\/illicit-drug.pdf."},{"key":"336_CR6","doi-asserted-by":"publisher","DOI":"10.31027\/ODPRN.2017.01","volume-title":"Latest trends in opioid-related deaths in Ontario: 1991 to 2015","author":"TGS Gomes","year":"2017","unstructured":"Gomes TGS, Martins D, et al. Latest trends in opioid-related deaths in Ontario: 1991 to 2015. Toronto: The Ontario Drug Policy Research Network; 2017."},{"key":"336_CR7","unstructured":"Opioid-related morbidity and mortality in Ontario [Internet]. Public Health Ontario. 2017. Available from: https:\/\/www.publichealthontario.ca\/en\/dataandanalytics\/pages\/opioid.aspx#\/trends. Accessed 29 Apr 2019."},{"key":"336_CR8","unstructured":"Budget 2017 brings additional federal funding to fight the opioid crisis [press release]. Health Canada; 2017. Retrieved from https:\/\/www.canada.ca\/en\/health-canada\/news\/2017\/04\/budget_2017_bringsadditionalfederalfundingtofighttheopioidcrisis.html."},{"key":"336_CR9","unstructured":"Federal Action on Opioids. Health Canada; 2017. Retrieved from https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-abuse\/prescription-drug-abuse\/opioids\/federal-actions.html."},{"key":"336_CR10","unstructured":"Ontario providing support to those affected by opioid crisis [press release]. Ontario Ministry of Health and Long-Term Care; 2017. Retrieved from https:\/\/news.ontario.ca\/mohltc\/en\/2017\/08\/ontario-providing-support-to-those-affected-by-opioid-crisis.html."},{"key":"336_CR11","doi-asserted-by":"crossref","unstructured":"Young MM, Pirie T, Buxton JA, Hosein FS. The rise of overdose deaths involving fentanyl and the value of early warning. Canadian Journal of Addiction. 2015;6:13.","DOI":"10.1097\/02024458-201512000-00004"},{"key":"336_CR12","doi-asserted-by":"crossref","unstructured":"Strike C, Watson TM. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int J Drug Policy. 2019.","DOI":"10.1016\/j.drugpo.2019.02.005"},{"key":"336_CR13","doi-asserted-by":"crossref","unstructured":"Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59\u201366.","DOI":"10.1016\/j.drugpo.2018.10.001"},{"key":"336_CR14","unstructured":"Report and recommendations on the opioid crisis in Canada. 2016. Retrieved from http:\/\/publications.gc.ca\/collections\/collection_2016\/parl\/xc62-1\/XC62-1-1-421-6-eng.pdf."},{"key":"336_CR15","unstructured":"Toronto overdose action plan: prevention and response. Toronto Public Health; 2017. Retrieved from http:\/\/app.toronto.ca\/tmmis\/viewAgendaItemHistory.do?item=2017.HL18.3."},{"key":"336_CR16","unstructured":"Recommendations of the mayors\u2019 task force on the opioid crisis. Big-City Mayors\u2019 Caucus, Federation of Canadian Municipalities; 2017. Retrieved from https:\/\/fcm.ca\/Documents\/issues\/Opioid_Crisis_EN.pdf."},{"key":"336_CR17","unstructured":"Factsheet on drug checking in Europe. Trans European Drugs Information (TEDI) Workgroup; 2011. Retrieved from https:\/\/www.ecstasydata.org\/text\/2011\/2011_tedi_factsheet_on_drug_checking_in_europe.pdf."},{"key":"336_CR18","unstructured":"Benschop A, Rabes M, Korf D. Pill testing, ecstasy & prevention. Eine wis. 2002."},{"issue":"2","key":"336_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/dta.1954","volume":"9","author":"TM Brunt","year":"2017","unstructured":"Brunt TM, Nagy C, B\u00fccheli A, Martins D, Ugarte M, Beduwe C, et al. Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project. Drug Testing and Analysis. 2017;9(2):188\u201398.","journal-title":"Drug Testing and Analysis."},{"key":"336_CR20","doi-asserted-by":"crossref","unstructured":"Martins D, Barratt MJ, Pires CV, Carvalho H, Vilamala MV, Espinosa IF, et al. The detection and prevention of unintentional consumption of DOx and 25x-NBOMe at Portugal\u2019s Boom Festival. Human Psychopharmacology: Clinical and Experimental. 2017;32(3).","DOI":"10.1002\/hup.2608"},{"key":"336_CR21","doi-asserted-by":"crossref","unstructured":"Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend. 2015;147:109\u201315.","DOI":"10.1016\/j.drugalcdep.2014.11.033"},{"issue":"9","key":"336_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/dta.323","volume":"3","author":"TM Brunt","year":"2011","unstructured":"Brunt TM, Niesink RJ. The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison. Drug Testing and Analysis. 2011;3(9):621\u201334.","journal-title":"Drug Testing and Analysis."},{"issue":"12","key":"336_CR23","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/j.1360-0443.2009.02707.x","volume":"104","author":"N Vogels","year":"2009","unstructured":"Vogels N, Brunt TM, Rigter S, Van Dijk P, Vervaeke H, Niesink RJ. Content of ecstasy in the Netherlands: 1993\u20132008. Addiction. 2009;104(12):2057\u201366.","journal-title":"Addiction"},{"key":"336_CR24","doi-asserted-by":"crossref","unstructured":"Spruit IP. Monitoring synthetic drug markets, trends, and public health. Substance Use and Misuse. 2001;36(1-2):23\u201347.","DOI":"10.1081\/JA-100000227"},{"key":"336_CR25","doi-asserted-by":"crossref","unstructured":"Gin\u00e9 CV, Vilamala MV, Espinosa IF, Lladanosa CG, \u00c1lvarez NC, Fruit\u00f3s AF, et al. Crystals and tablets in the Spanish ecstasy market 2000\u20132014: are they the same or different in terms of purity and adulteration? Forensic Science International. 2016;263:164\u20138.","DOI":"10.1016\/j.forsciint.2016.04.016"},{"key":"336_CR26","doi-asserted-by":"crossref","unstructured":"Caudevilla-G\u00e1lligo F, Ventura M, Indave Ruiz BI, Forn\u00eds I. Presence and composition of cathinone derivatives in drug samples taken from a drug test service in Spain (2010\u20132012). Human Psychopharmacology: Clinical and Experimental. 2013;28(4):341\u20134.","DOI":"10.1002\/hup.2296"},{"key":"336_CR27","unstructured":"New federal initiatives to address the opioid crisis. Health Canada; 2017. Retrieved from https:\/\/www.canada.ca\/en\/health-canada\/news\/2017\/11\/new_federal_initiativestoaddresstheopioidcrisis.html."},{"key":"336_CR28","unstructured":"Reducing regulatory barriers to accessing treatment, and new funding for innovative projects. Health Canada; 2018. Retrieved from https:\/\/www.canada.ca\/en\/health-canada\/news\/2018\/03\/reducing-regulatory-barriers-to-accessing-treatment-and-new-funding-for-innovative-projects.html."},{"key":"336_CR29","doi-asserted-by":"crossref","unstructured":"Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017;14(1):52.","DOI":"10.1186\/s12954-017-0179-5"},{"key":"336_CR30","unstructured":"Maghsoudi N. Comparing models of drug checking services in Canada. Centre on Drug Policy Evaluation; 2018."},{"key":"336_CR31","unstructured":"Barratt MJ, Kowalski M, Maier LJ, Ritter A. Global review of drug checking services operating in 2017. Sydney, Australia: National Drug and Alcohol Research Centre, UNSW Sydney; 2018."},{"key":"336_CR32","unstructured":"Evidence brief: drug checking services as a harm reduction intervention. Public Health Ontario; 2017. Retrieved from https:\/\/www.publichealthontario.ca\/en\/eRepository\/Evidence_Brief_Drug_Checking_2017.pdf."},{"issue":"2","key":"336_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","volume":"13","author":"T Rhodes","year":"2002","unstructured":"Rhodes T. The \u2018risk environment\u2019: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85.","journal-title":"Int J Drug Policy"},{"key":"336_CR34","doi-asserted-by":"crossref","unstructured":"Firestone M, Goldman B, Fischer B. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications. Int J Drug Policy. 2009;20(1):90\u20132.","DOI":"10.1016\/j.drugpo.2008.02.016"},{"key":"336_CR35","volume-title":"Report of the Toronto and Ottawa Supervised Consumption Assessment Study","author":"A Bayoumi","year":"2012","unstructured":"Bayoumi A, Strike C, Brandeau ML, Degani N, Fischer B, Glazier R, et al. Report of the Toronto and Ottawa Supervised Consumption Assessment Study. Toronto: St. Michael's Hospital and the Dalla Lana School of Public Health, University of Toronto; 2012."},{"key":"336_CR36","doi-asserted-by":"crossref","unstructured":"Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193\u2013201.","DOI":"10.1016\/j.drugpo.2008.10.003"},{"key":"336_CR37","doi-asserted-by":"crossref","unstructured":"Frajzyngier V, Neaigus A, Gyarmathy VA, Miller M, Friedman SR. Gender differences in injection risk behaviors at the first injection episode. Drug Alcohol Depend. 2007;89(2-3):145\u201352.","DOI":"10.1016\/j.drugalcdep.2006.12.021"},{"key":"336_CR38","doi-asserted-by":"crossref","unstructured":"Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80(1):137\u201346.","DOI":"10.1093\/jurban\/jtg137"},{"key":"336_CR39","volume-title":"\u2018Nothing about us, without us\u2019: participation and involvement of drug users in health services and policy making","author":"K Schiffer","year":"2011","unstructured":"Schiffer K. \u2018Nothing about us, without us\u2019: participation and involvement of drug users in health services and policy making. Amsterdam: Correlation Network; 2011."},{"key":"336_CR40","doi-asserted-by":"crossref","unstructured":"Magura S. Validating self-reports of illegal drug use to evaluate National Drug Control Policy: a reanalysis and critique. Eval Program Plann. 2010;33(3):234\u20137.","DOI":"10.1016\/j.evalprogplan.2009.08.004"},{"key":"336_CR41","doi-asserted-by":"crossref","unstructured":"Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008;8(1):405.","DOI":"10.1186\/1471-2458-8-405"},{"key":"336_CR42","first-page":"S319","volume":"66","author":"S Baral","year":"2014","unstructured":"Baral S, Holland CE, Shannon K, Logie C, Semugoma P, Sithole B, et al. Enhancing benefits or increasing harms: community responses for HIV among men who have sex with men, transgender women, female sex workers, and people who inject drugs. JAIDS. 2014;66:S319\u2013S28.","journal-title":"JAIDS"},{"key":"336_CR43","doi-asserted-by":"crossref","unstructured":"Werb D, Garfein R, Kerr T, Davidson P, Roux P, Jauffret-Roustide M, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduct J. 2016;13:25.","DOI":"10.1186\/s12954-016-0114-1"},{"key":"336_CR44","doi-asserted-by":"crossref","unstructured":"Doherty MC, Edgar Monterroso MD MPH. Gender differences in the initiation of injection drug use among young adults. J Urban Health. 2000;77(3):396\u2013414.","DOI":"10.1007\/BF02386749"},{"key":"336_CR45","doi-asserted-by":"crossref","unstructured":"Tsai JS, Lin GL. Drug-testing technologies and applications. Drugs of Abuse: Springer; 2005. p. 29-69.","DOI":"10.1007\/978-1-59259-951-6_3"},{"issue":"7","key":"336_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jat\/27.7.513","volume":"27","author":"J Day","year":"2003","unstructured":"Day J, Slawson M, Lugo R, Wilkins D. Analysis of fentanyl and norfentanyl in human plasma by liquid chromatography-tandem mass spectrometry using electrospray ionization. Journal of Analytical Toxicology. 2003;27(7):513\u20136.","journal-title":"Journal of Analytical Toxicology."},{"key":"336_CR47","unstructured":"Proctor J, Larsen K. \u2018An exceptionally high toll\u2019: Fentanyl, overdoses claim 488 in B.C. CBCca. 2016 September 21."},{"key":"336_CR48","unstructured":"Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in high-dose opioid prescribing in Canada. Can Fam Physician. 2014;60(9):826\u201332."},{"key":"336_CR49","unstructured":"TPH. Toronto Overdose Information system: calls to paramedic services for suspected opioid overdoses - geographic information. Toronto: Toronto Public Health; 2019."},{"key":"336_CR50","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Reseach in Psychology. 2006;3(2):77\u2013101.","DOI":"10.1191\/1478088706qp063oa"},{"key":"336_CR51","doi-asserted-by":"crossref","unstructured":"Morse JM. The significance of saturation. Qualitative Health Research 1995. Contract No.: 2.","DOI":"10.1177\/104973239500500201"},{"key":"336_CR52","doi-asserted-by":"crossref","unstructured":"Leung L. Validity, reliability, and generalizability in qualitative research. J Family Med Prim Care. 2015;4(3):324\u20137.","DOI":"10.4103\/2249-4863.161306"},{"issue":"7294","key":"336_CR53","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/bmj.322.7294.1115","volume":"322","author":"RS Barbour","year":"2001","unstructured":"Barbour RS. Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? BMJ (Clinical Research Edition). 2001;322(7294):1115\u20137.","journal-title":"BMJ (Clinical Research Edition)."},{"key":"336_CR54","doi-asserted-by":"crossref","unstructured":"Grundy C, Steinbach R, Edwards P, Green J, Armstrong B, Wilkinson P. Effect of 20 mph traffic speed zones on road injuries in London, 1986-2006: Controlled interrupted time series analysis. BMJ. 2009, 339:b4469.","DOI":"10.1136\/bmj.b4469"},{"issue":"7","key":"336_CR55","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/add.13350","volume":"111","author":"D Werb","year":"2016","unstructured":"Werb D, Strathdee SA, Vera A, Arredondo J, Beletsky L, Gonzalez-Zuniga P, et al. Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana, Mexico. Addiction. 2016;111(7):1246\u201356.","journal-title":"Addiction"},{"issue":"9775","key":"336_CR56","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","volume":"377","author":"BDL Marshall","year":"2011","unstructured":"Marshall BDL, Milloy MJ, Wood E, Montaner JSG, Kerr T. Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429\u201337.","journal-title":"Lancet"},{"key":"336_CR57","unstructured":"Fotheringham AS, Brunsdon C, Charlton M. Geographically weighted regression: the analysis of spatially varying relationships: John Wiley & Sons; 2003."},{"key":"336_CR58","unstructured":"Teddlie C, Tashakkori A. Foundations of mixed-methods research: integrating quantitative and qualitative approaches in the social and behavioral sciences. USA: Sage Publications Inc; 2009."},{"key":"336_CR59","doi-asserted-by":"crossref","unstructured":"McNeil R, Small W, Wood E, Kerr T. Hospitals as a \u2018risk environment\u2019: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014;105:59\u201366.","DOI":"10.1016\/j.socscimed.2014.01.010"},{"key":"336_CR60","doi-asserted-by":"crossref","unstructured":"Agar M. Toward a qualitative epidemiology. Qual Health Res. 2003;13(7):974\u201386.","DOI":"10.1177\/1049732303256886"},{"key":"336_CR61","doi-asserted-by":"crossref","unstructured":"Lopez AM, Bourgois P, Wenger LD, Lorvick J, Martinez AN, Kral AH. Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco. Int J Drug Policy. 2013;24(2):101\u20139.","DOI":"10.1016\/j.drugpo.2012.12.004"},{"key":"336_CR62","doi-asserted-by":"crossref","unstructured":"Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242\u20135.","DOI":"10.1016\/j.drugalcdep.2018.06.020"},{"key":"336_CR63","unstructured":"U.S. drug overdose deaths continue to rise; increase fueled by synthetic opioids [press release]. Centers for Disease Control and Prevention, 2018-03-29\u2009T03:14:28Z 2018. Retrieved from https:\/\/www.cdc.gov\/media\/releases\/2018\/p0329-drug-overdose-deaths.html."},{"key":"336_CR64","unstructured":"Deaths related to drug poisoning in England and Wales: 2016 registrations. Office for National Statistics; 2017. Retrieved from https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2016registrations."},{"key":"336_CR65","unstructured":"Charlois T, editor Safer Nightlife in Europe. 5th Meeting EXASS Network 2009: Council of Europe\u2019s Pompidou Group."},{"key":"336_CR66","doi-asserted-by":"crossref","unstructured":"Hungerbuehler I, Buecheli A, Schaub M. Drug Checking: A prevention measure for a heterogeneous group with high consumption frequency and polydrug use-evaluation of Zurich\u2019s drug checking services. Harm Reduc J. 2011;8(1):16.","DOI":"10.1186\/1477-7517-8-16"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0336-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0336-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:23:30Z","timestamp":1611707010000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0336-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0336-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"15 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research Ethics Board approval has been obtained for this research study from Providence St. Joseph\u2019s and St. Michael\u2019s Healthcare, Toronto Public Health, Centre for Addiction and Mental Health, and University of Toronto.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}